Egetis shares jump about 13% after US FDA approval of Emcitate
Rare disease drugmaker Egetis surged about 13% after US FDA approval of its Emcitate drug, with Van Lanschot Kempen saying the approval unlocks the firm’s largest opportunity and pointing to uptake expectations and commercial outlook factors including higher WAC and a priority review voucher worth up to $220 million.